Lavender Capsules Menopause

By Sophora Health Editorial Team ·  Medically reviewed  ·  Published July 2026  ·  Last reviewed July 2026

The lavender diffuser did not work. This is not a criticism of the diffuser. It was doing exactly what it was designed to do, which is make the room smell pleasant. What it was not doing was crossing the blood-brain barrier, modulating GABA-A receptors, or reducing cortisol. Those effects require a different form of lavender entirely.

Silexan is an oral, standardised extract of lavender oil. It is not aromatherapy. It is not a pillow spray. It is a specific pharmaceutical-grade preparation that has been through three randomised controlled trials and received formal regulatory approval in Germany as a treatment for anxiety. It works through mechanisms that no amount of inhaled lavender can replicate, and it has a specific dose and a specific product form.

The confusion between “lavender is calming” and “lavender supplements work for menopause” is understandable. The wellness industry conflates them constantly. This article separates them cleanly.

What silexan actually is

Silexan is a specific, patented preparation of lavender oil produced by Schwabe Pharmaceuticals in Germany. It is derived from Lavandula angustifolia and standardised to a precise composition of active compounds, principally linalool and linalyl acetate, at concentrations that do not vary between batches. This standardisation is what makes clinical trial results replicable and why the evidence for silexan does not transfer to other lavender products.

The oral capsule delivers silexan directly to the gastrointestinal tract, where it is absorbed into the bloodstream and crosses the blood-brain barrier. This delivery route is fundamentally different from inhalation. Inhaled lavender produces a mild, temporary effect on mood through olfactory pathways. The capsule produces a direct pharmacological effect on neuroreceptors through systemic absorption.

How it works: the mechanism behind the evidence

Silexan acts through two primary pathways that are directly relevant to perimenopausal symptoms.

GABA-A receptor modulation

The primary mechanism is partial agonism at GABA-A receptors. GABA is the brain’s primary inhibitory neurotransmitter: the signal that keeps neural activity calm and able to sustain sleep. Silexan binds to GABA-A receptors and enhances their inhibitory effect without the full agonism of benzodiazepines. It calms the nervous system without sedating it into the unrestorative sleep that prescription hypnotics can produce.

This mechanism overlaps directly with the progesterone-GABA withdrawal problem in perimenopause. Progesterone, via its metabolite allopregnanolone, modulates GABA-A receptors as a natural neurosteroid. As progesterone falls in perimenopause, the brain’s GABA-A system loses calming input. Silexan provides partial, non-hormonal support to the same receptor system. It does not replace progesterone. It supports the system that progesterone was supporting, through a different but complementary binding site.

Serotonin receptor modulation and cortisol reduction

The secondary mechanism involves modulation of serotonin 1A receptors, which regulate mood, anxiety, and stress response. Through this pathway, silexan produces a mild antidepressant effect and reduces the amplitude of the cortisol stress response. This is directly relevant to the cortisol dysregulation mechanism in perimenopausal sleep disruption. The early-morning cortisol spike that wakes women at 3am is partly driven by HPA axis dysregulation, and serotonin receptor activity modulates the HPA axis.

The combination of GABA-A modulation and serotonin receptor activity makes silexan relevant to anxiety, low mood, and sleep disruption simultaneously. It produces a profile similar to low-dose antidepressants but without the side effects of SSRIs or the dependence risk of benzodiazepines.

The clinical evidence: what the trials actually found

There are three published randomised controlled trials on silexan, plus a substantial body of observational and open-label data. The three RCTs are the ones that matter for assessing whether the evidence is real.

Trial 1 (Kasper et al., 2010. Pharmacopsychiatry). Silexan 80mg versus lorazepam 0.5mg versus placebo in adults with mixed anxiety-depression. Silexan produced comparable anxiety reduction to lorazepam without the sedation or dependence risk. This was the first trial to establish that silexan had a clinically meaningful anxiolytic effect comparable to a prescription benzodiazepine. That is a high bar for a plant-derived supplement, and it cleared it.

Trial 2 (Kasper et al., 2014. International Journal of Neuropsychopharmacology). Silexan 80mg versus paroxetine 20mg versus placebo in adults with generalised anxiety disorder. Silexan produced significant reduction in Hamilton Anxiety Scale scores compared to placebo, with a comparable effect to paroxetine in the primary anxiety measure and fewer side effects. This was the trial that triggered the BfArM formal approval in Germany.

Trial 3 (Woelk and Schlaefke, 2010. Phytomedicine). Silexan 80mg versus valerian in adults with anxiety-related sleep disruption. Silexan produced significantly better sleep quality improvement than valerian at equivalent doses, with the improvement driven by both reduced sleep onset time and reduced early morning awakening. The early morning awakening component is specifically relevant to perimenopausal sleep disruption.

These are not small pilot studies. The combined evidence led to formal pharmaceutical approval in Germany and clinical guideline inclusion in multiple countries. The German BfArM regulatory process applies pharmaceutical-grade standards to herbal preparations. That silexan met those standards is a meaningful signal in a category where most products do not.

What it does not do

Silexan does not reduce hot flush frequency. The trials did not measure vasomotor symptoms. There is no credible mechanism by which GABA-A modulation or serotonin receptor activity would directly reduce the thermoregulatory dysfunction driving hot flushes. Women whose primary complaint is heat and sweating rather than anxiety and sleep disruption will find silexan less relevant than magnesium glycinate, phytoestrogens, or environmental cooling.

It does not work overnight. Most participants in the RCTs noticed meaningful improvement in anxiety and sleep after two to four weeks of consistent nightly use. This reflects the time required for neuroreceptor adaptation rather than an acute pharmacological effect. Taking it for three nights and concluding it does not work is not a fair assessment of the evidence.

It does not replace hormone therapy. For women with severe vasomotor symptoms, significant bone density concerns, or cardiovascular risk factors associated with estrogen decline, hormone therapy addresses the underlying hormonal mechanism. Silexan addresses the anxiety and sleep disruption that are often associated with perimenopause but does not restore the hormonal environment. These are not competing interventions. They work on different systems.

Dose, form, and what to look for

Dose: 80mg silexan nightly. This is the dose used in all three RCTs. Higher doses have not produced meaningfully better outcomes in published research, and lower doses have not been studied. The 80mg dose is the evidence-supported specification.

Form: Oral capsule only. Silexan must be taken orally to produce the systemic absorption that drives the mechanism. Lavender essential oil taken orally is not the same preparation and should not be consumed internally without specific medical supervision. Lavender aromatherapy, topical lavender oil, and lavender tea are different preparations with different (and much weaker) evidence bases for anxiety and sleep.

Where to find it: In the UK, Kalms Lavender One-A-Night is the most widely available option, sold at Boots and Lloyds pharmacies. In Germany, Lasea is the original branded product. In Australia and the US, silexan capsules are available in health food stores under various brand names. The key specification is “silexan” or “lavender oil extract 80mg” on the label.

Timing: Take nightly, 30 to 60 minutes before bed, to align the peak absorption with sleep onset. Unlike magnesium glycinate, silexan does not need to be taken at a specific time relative to food. It can be taken on an empty or full stomach.

What research and regulatory context from around the world shows

Silexan has an unusually strong international regulatory and research footprint for a plant-derived supplement. Most herbal preparations have evidence from one or two countries and one or two studies. Silexan has multi-country regulatory approval, multi-country clinical uptake, and an independently replicated evidence base.

Germany. The origin of silexan and the strongest regulatory context. The BfArM, Germany’s federal pharmaceutical authority, approved silexan as a prescription-grade medicinal product for anxiety. This required meeting the same evidence standards applied to synthetic pharmaceuticals. Lasea, the branded silexan product, is prescribed by German doctors and covered by some German health insurers. This is the highest regulatory bar any herbal anxiety treatment has cleared in a major pharmaceutical market.

United Kingdom. Kalms Lavender is the most widely available silexan product, sold over the counter at pharmacies including Boots, Lloyds, and independent chemists. The UK Medicines and Healthcare products Regulatory Agency registers it as a traditional herbal remedy at the 80mg silexan dose. NICE does not currently list silexan in its menopause guidelines but recognises it in its generalised anxiety disorder guidance as an option for mild to moderate symptoms.

North America. Silexan is available in the US as a supplement rather than a pharmaceutical, meaning it has not gone through FDA drug approval. The evidence base is identical to the European trials. Canadian natural health product regulations list lavender oil extract at 80mg as acceptable for anxiety symptom relief. Clinical uptake in North America is growing as the trial evidence becomes more widely cited in integrative medicine.

Australia. The Therapeutic Goods Administration registers silexan-containing products under the complementary medicines framework. Silexan capsules at 80mg are available in Australian health food stores and pharmacies. The Jean Hailes Foundation references oral lavender as a non-hormonal option in perimenopause anxiety management.

Middle East and South Asia. Lavender has extensive traditional use in Iranian, Indian, and broader Middle Eastern medicine, primarily as aromatherapy and herbal teas. The oral silexan preparation is a pharmacological development of that traditional knowledge base. Iranian researchers have investigated oral lavender preparations for anxiety, with findings consistent with the European RCT data. Uptake of oral silexan is growing in urban markets across both regions.

East Asia. Japanese and South Korean integrative medicine interest in silexan has grown following the publication of the German RCT data. Lavender is well-integrated into Japanese wellness culture in aromatherapy contexts. The transition to oral preparation represents a pharmacological shift that is gaining traction in clinical and consumer markets.

Latin America. Lavender is widely used in traditional herbal medicine across Brazil, Argentina, and Mexico. Oral lavender supplements are increasingly available in urban health food markets. Brazilian researchers have noted consistency between silexan’s mechanism and local herbal anxiety traditions, though peer-reviewed studies specifically on silexan in Latin American populations are limited. The mechanistic evidence is transferable regardless of population.

Africa. Lavender cultivation and use in traditional medicine occurs across North Africa and in South African aromatherapy markets. Oral silexan capsules are available through international retail channels in major urban African markets. The evidence base applies universally; regional peer-reviewed verification of silexan specifically is an area of active development.

Using silexan alongside other interventions

Silexan combines well with magnesium glycinate because the two act on the same receptor family (GABA-A) through different binding sites, producing complementary rather than redundant effects. Taking both is not overkill. It is addressing the GABA-A system from two independent pharmacological angles simultaneously, which is relevant when the progesterone-GABA withdrawal is severe enough to require more than one intervention.

Silexan can be taken alongside hormone therapy without known interactions. It can be taken alongside SSRIs with caution. The serotonin receptor modulation creates a theoretical interaction risk with serotonergic medications. Consult a pharmacist or doctor before combining them. The risk is theoretical rather than established in published case reports, but it warrants the conversation.

It does not interact with magnesium, ashwagandha, phytoestrogens, or melatonin in any documented way. For women building a multi-intervention approach to perimenopausal sleep and anxiety, silexan integrates cleanly into the stack.

“The diffuser was not useless. It smelled good and made the bedroom feel intentional. What it was not doing was modulating GABA-A receptors. The capsule does that. The distinction is not pedantic. It is the difference between a pleasant evening ritual and a clinical intervention with three RCTs behind it.”

Related reading

Frequently asked questions

Does lavender actually help with menopause symptoms?

Oral lavender silexan at 80mg has RCT evidence for anxiety and sleep disruption, both of which are prominent perimenopausal symptoms. It does not have evidence for hot flush reduction. Aromatherapy lavender has a different and much weaker evidence base. The form of lavender matters considerably: the capsule is the form with the clinical evidence.

Is Kalms Lavender the same as silexan?

Yes. Kalms Lavender One-A-Night contains 80mg silexan per capsule. It is the UK’s most widely available silexan product and is the dose and formulation used in the clinical trials. The Kalms brand is sold in Boots, Lloyds, and other UK pharmacies without a prescription.

Can I take lavender capsules with antidepressants?

Consult a pharmacist or doctor before combining silexan with SSRIs or SNRIs. The serotonin receptor modulation mechanism creates a theoretical interaction risk with serotonergic medications. The risk is theoretical rather than documented in case reports, but the conversation is worth having. Silexan can be taken alongside hormone therapy, magnesium, and ashwagandha without known interactions.

How long does lavender silexan take to work?

Two to four weeks of consistent nightly use before a clear effect is typically established. Some women notice lighter anxiety and faster sleep onset in the first week. The full effect on sleep maintenance and mood tends to emerge over two to four weeks as neuroreceptor adaptation develops. Stopping after a few nights does not produce a fair assessment.

Is silexan safe for long-term use?

The longest RCT ran for ten weeks. Open-label studies and post-marketing surveillance in Germany, where it has been prescribed since 2009, have not identified safety signals at the 80mg dose. It does not produce dependence and does not cause the withdrawal effects associated with benzodiazepines. As with any supplement, a doctor review is appropriate for use beyond three to six months, particularly if other medications are involved.

Last reviewed: July 2026  ·  Review due: October 2026  ·  Not therapy. Not medical advice. For your own use and understanding only.  ·  mysophora.com